The 11 most recent market catalysts affecting $TYRA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 65
Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40
Oppenheimer analyst Mazahir Alimohamed reiterated an 'Outperform' rating on Tyra Biosciences, signaling continued confidence in the company's fundamentals. However, the price targe…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Tyra Biosciences shares are trading higher after the company announced pricing of an underwritten offering of 9,079,000 common shares at $22.03 each and pre‑funded warrants for 9,078,529 shares at $22.029 each.
The headline indicates a successful capital raise for Tyra Biosciences, which typically leads to dilution and downward pressure on stock price. However, the stock is trading higher…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 85
Tyra Biosciences Prices Underwritten Offering Of 9,079,000 Shares And Warrants At $22.03 Per Unit
Tyra Biosciences is conducting a substantial underwritten offering to raise $400 million through the sale of common stock and pre-funded warrants. This capital raise is crucial for…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 55
Tyra Biosciences Files Prospectus To Sell Mixed Securities Shelf Of Undisclosed Amount
Tyra Biosciences has filed a 'mixed securities shelf' registration, which is a common corporate finance maneuver. This means the company has pre-registered with the SEC to sell var…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 75
Tyra Biosciences shares are trading lower after the company announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer.
The headline indicates a significant negative reaction to clinical trial results for Tyra Biosciences. Initial Phase 2 results are a critical milestone for biotechnology companies,…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 92
Tyra Biosciences Says Phase 2 SURF302 Study Of Oral Dabogratinib In Low-Grade IR NMIBC Showed 79% ORR, 64% Best Overall Complete Response Rate At 60 mg QD; Says 100% ORR In Single Marker Lesion Patients, Identifies 60 mg As Phase 3 Adjuvant Dose
This headline represents a major corporate catalyst for Tyra Biosciences. The exceptionally high Overall Response Rate (ORR) of 79% and Complete Response Rate (CRR) of 64% for dabo…
Sep 4, 2026
Corporate Catalyst
Bullish
Impact 75
Tyra Biosciences shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $45 price target.
The reiteration of a 'Buy' rating and a strong price target from a reputable analyst firm like HC Wainwright & Co. acts as a significant positive catalyst for Tyra Biosciences. Thi…
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 75
Tyra Biosciences To Discuss Initial Clinical Results From SURF302 Phase 2 Study Evaluating Oral Dabogratinib For IR NMIBC In Conference Call And Webcast On September 9
Tyra Biosciences has scheduled a conference call and webcast for September 9, 2026, to present initial clinical results from its Phase 2 SURF302 study of dabogratinib for intermedi…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Tyra Biosciences shares are trading lower after the company reported worse-than-expected Q2 EPS results.
This headline represents a significant corporate catalyst, directly impacting Tyra Biosciences due to its failure to meet earnings expectations. Such an event often leads to immedi…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 92
Tyra Biosciences Q2 EPS $(0.69) Misses $(0.65) Estimate
Tyra Biosciences (TYRA) announced Q2 earnings per share of $(0.69), which fell short of the consensus estimate of $(0.65). This miss, coupled with a substantial 46.81% increase in …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.